Marc Banjak
Förmögenhet: 29 500 $ per 2026-09-30
Förmögenhet: 29 500 $ per 2026-09-30
Mr. Marc A. Banjak is a Secretary & General Counsel at iBio, Inc. Mr. Banjak was previously employed as a General Counsel by Dova Pharmaceuticals, Inc., a General Counsel by Istari Oncology, Inc., and a Member by The Colorado Bar Association.
He received his undergraduate degree from Franklin & Marshall College and a graduate degree from Sturm College of Law.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
IBIO, INC. 0,07 % | 2026-09-01 | 25 000 ( 0,07 % ) | 29 500 $ | 2026-09-30 |
| Företag | Position | Start |
|---|---|---|
| IBIO, INC. | Generell Rådgivare | - |
| Företag | Position | Slut |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Generell Rådgivare | 2021-04-01 |
The Colorado Bar Association | Företagsledare/Principal | - |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Comptroller/Controller/Revisor | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 6 |
|---|---|
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Colorado Bar Association | |
iBio, Inc.
iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Sturm College of Law
Sturm College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån